EP. 10 Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status
September 5th, 2026B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial CancerDana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.Read more